{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_2009_0155791_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"098-813-248-648-753"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":6804,"type":"PATENT","title":"Univ Sydney Patent Portfolio","description":"Searched ' Univ Sydney ' for patent collection. Added owners (US), expanded by simply family and date range set as 01/Jan/2000 - 01/ Apr/ 2015\n","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":47811,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2015-05-04T02:51:05Z","updated":"2015-05-04T04:00:52Z","lastEventDate":"2015-05-04T04:00:52Z"},{"id":7071,"type":"PATENT","title":"Peter MacCallum Cancer Centre","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":365,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8708,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants= ' Peter MacCallum Cancer Centre' ' Peter Mac* Can*' ' Peter MacCallum Can' ' Inst Pete* Mac* Can*' 'Peter MacCallum Cancer Institute' 'Pete* MacC* Can* Inst*'
Search Owners (US) = ' Peter MacCallum Cancer Centre' ' Peter Mac* Can*' ' Peter MacCallum Can' ' Inst Pete* Mac* Can*' 'Peter MacCallum Cancer Institute' 'Pete* MacC* Can* Inst*'
Select for logical variants
Add to collection
Select all the patents in the collection and expand by simple families
Add to collection
total patents= 205
........Annie Second search.....
Search Applicants and Owners(US) respectively = ' Pet* Mac* Can* Inst*', ' The Cancer Institute Board', 'Can* Inst* Peter Mac*','Pet* Mac* Can* Cen*'
Add to collection
Select all the patents in the collection and expand by simple families
Add to collection
Total Patents= 346
Search Applicants and Owners separately: \"Aarhus Univ*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 786
Search Applicants= ' Peter MacCallum Cancer Centre' ' Peter Mac* Can*' ' Peter MacCallum Can' ' Inst Pete* Mac* Can*' 'Peter MacCallum Cancer Institute' 'Pete* MacC* Can* Inst*'
Search Owners (US) = ' Peter MacCallum Cancer Centre' ' Peter Mac* Can*' ' Peter MacCallum Can' ' Inst Pete* Mac* Can*' 'Peter MacCallum Cancer Institute' 'Pete* MacC* Can* Inst*'
Select for logical variants
Add to collection
Select all the patents in the collection and expand by simple families
Add to collection
total patents= 205
........Annie Second search.....
Search Applicants and Owners(US) respectively = ' Pet* Mac* Can* Inst*', ' The Cancer Institute Board', 'Can* Inst* Peter Mac*','Pet* Mac* Can* Cen*'
Add to collection
Select all the patents in the collection and expand by simple families
Add to collection
Total Patents= 346
Search Applicants and Owners separately: \"Aarhus Univ*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 786
modifying said CpG-containing nucleic acid using an agent which modifies at least one unmethylated cytosine in said methylated CpG-containing nucleic acid, and\n
amplifying said CpG-containing nucleic acid by means of at least one methylation-independent oligonucleotide primer."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said at least one methylation-independent oligonucleotide primer comprises at least one CpG dinucleotide"],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said at least one methylation-independent oligonucleotide primer comprises at least two CpG dinucleotides."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 2, wherein the at least one CpG dinucleotide is located in the 5′-end of the oligonucleotide primer"],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 4, wherein said at least one CpG dinucleotide is located within the first 10 nucleotides of the 5′-end of said at least one methylation-independent oligonucleotide primer."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 5, wherein said at least one CpG dinucleotide is located immediately after the first nucleotide of the 5′-end of said at least one methylation-independent oligonucleotide primer."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said agent is bisulphite."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said unmethylated cytosine is modified to uracil."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said amplifying step is performed by a polymerisation reaction."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 9, wherein said polymerisation reaction is a polymerase chain reaction (PCR)"],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 10, wherein said PCR comprises the steps of\n
a) melting a CpG-containing nucleic acid template,\n
b) annealing at least one methylation-independent oligonucleotide primer to said CpG-containing nucleic acid template, and\n
c) elongating said at least one methylation-independent oligonucleotide primer."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein in said amplifying step is achieved by means of at least two methylation-independent oligonucleotide primers."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein in said amplifying step, said at least one methylation-independent oligonucleotide primer is able to hybridise to methylated and unmethylated CpG-containing nucleic acids after modification."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said sample is selected from the group consisting of breast tissue, ovarian tissue, uterine tissue, colon tissue, prostate tissue, lung tissue, renal tissue, thymus tissue, testis tissue, hematopoietic tissue, bone marrow, urogenital tissue, expiration air, stem cells, stem cell, body fluids, sputum, urine, blood and sweat."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said sample is selected from the group consisting of breast tissue, ovarian tissue, uterine tissue, colon tissue, prostate tissue and lung tissue."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein the at least one methylation-independent oligonucleotide primer comprise between 10 and 200 nucleotides."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein the at least one methylation-independent oligonucleotide primers comprise between 15 and 60 nucleotides."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said at least one methylation-independent oligonucleotide primer is selected from the group consisting of SEQ ID NO.: 46-151."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said at least one methylation-independent oligonucleotide primer is selected from the group consisting of SEQ ID NO.: 185-250."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 12, wherein said at least two methylation-independent oligonucleotide primer is SEQ ID NO.: 136 and 137."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said at least one methylation-independent oligonucleotide primers is SEQ ID NO.: 138 and 139."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 12, wherein said at least two methylation-independent oligonucleotide primers is SEQ ID NO.: 142 and 143."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 12, wherein said at least two methylation-independent oligonucleotide primers is SEQ ID NO.: 144 and 145."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 12, wherein said at least two methylation-independent oligonucleotide primers is SEQ ID NO.: 146 and 147."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 11, wherein the primer annealing temperature during amplification of said CpG-containing nucleic acid is between 40 and 75 degrees Celsius."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 11, wherein the primer annealing temperature during amplification of said CpG-containing nucleic acid is 60 degrees Celsius."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 11, wherein the primer annealing temperature during amplification of said CpG-containing nucleic acid is 64 degrees Celsius."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein the presence of methylated CpG-containing nucleic acid is indicative of a disorder."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein the absence of methylated CpG-containing nucleic acid is indicative of a disorder."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 28, wherein said disorder is selected from the group consisting of Alzheimer's disease, atherosclerosis, breast cancer, bladder cancer, ovarian cancer, melanoma, prostate cancer, lung cancer, renal cancer, colon cancer, gastric cancer, cervical cancer, leukaemia, low grade astrocytoma, anaplastic astrocytoma, glioblastoma, haematopoietic disorders, medulloblastoma, leukemia, metabolic disorders, endometrial cancer, neuroblastoma, diffuse large B-cell lymphoma, developmental disorders, Prader-Willi syndrome, Angelman syndrome and imprinting disorders."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 28, wherein said disorder is selected from the group consisting of breast cancer, bladder cancer, ovarian cancer, melanoma, prostate cancer, lung cancer, colon cancer, endometrial cancer and leukaemia."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 28, wherein said disorder is colon cancer."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 28, wherein said disorder is breast cancer."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said at least one methylation-independent oligonucleotide primers hybridizes to a target CpG-containing nucleic acid sequence, wherein methylation of said target sequence is indicative of the presence of a disorder."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said at least one oligonucleotide primer hybridizes to a target CpG-containing nucleic acid sequence of a gene selected from the group consisting of PPP3CC, BNIP3, MGMT, SNRPN, GSTP1, RARB2, RASSF1A, TIMP3, APC, beta-Actin, PTGS2 and 14-3-3 sigma."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said at least one oligonucleotide primer hybridizes to a target CpG-containing nucleic acid sequence of a gene selected from the group consisting of CHD1, COX2, PRSS3, PYCARD, BIN1, BRCA1, LATS2, PITX2, BCL2, EYA4, GSK3B, MLH1, TIMP-3, MSH6, MTHFR, PTEN, SFN, CD109, ERS1, PCDH10, DAPK1, FHIT, P16ink4a, PRSS3, RASSF1, TMS1, CAGE-1, GPR150, ITGA8, PRDX2, SYK, ALX3, HOXD11, PTPRO, WWOX, ABHD9, CAV9, GPR78, GSTP1, HIC1, PTGS2, CSMD1, C10orf59, MGMT, BNIP3, PPP3CC CSMD1, MAP3k7, C10orf59 and GRIFK2."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said at least one oligonucleotide primer hybridizes to a target CpG-containing nucleic acid sequence of a gene selected from the group consisting of SEQ ID NO.: 1-45, or the complement thereof."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said at least one oligonucleotide primer hybridizes to a target CpG-containing nucleic acid sequence of a gene selected from the group consisting of SEQ ID NO.: 9-13, or the complement thereof."],"number":38,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said at least one oligonucleotide primer hybridizes to a target CpG-containing nucleic acid sequence of a gene selected from the group consisting of SEQ ID NO.: 5-8, or the complement thereof."],"number":39,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said at least one oligonucleotide primer hybridizes to a target CpG-containing nucleic acid sequence of a gene selected from the group consisting of SEQ ID NO.: 21-26, or the complement thereof."],"number":40,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said at least one oligonucleotide primer hybridizes to a target CpG-containing nucleic acid sequence as defined by SEQ ID NO.: 44 or 45, or the complement thereof."],"number":41,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said at least one oligonucleotide primer hybridizes to a target CpG-containing nucleic acid sequence as defined by SEQ ID NO.: 42, or the complement thereof."],"number":42,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said at least one oligonucleotide primer hybridizes with a target CpG-containing nucleic acid sequence, which is at least 97% identical to the target sequence, or the complement thereof."],"number":43,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein the relative amount of methylated CpG-containing nucleic acid in said sample is between 40-60%."],"number":44,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein the relative amount of methylated CpG-containing nucleic acid in said sample is below 50%."],"number":45,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein the relative amount of methylated CpG-containing nucleic acid in said sample is below 1%."],"number":46,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein the relative amount of methylated CpG-containing nucleic acid in said sample is below 0.1%."],"number":47,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, comprising the primers according to SEQ ID NO.: 46 and 47 for the detection of methylation status of CHD1 as defined in SEQ ID NO.: 1, wherein the primer annealing temperature during amplification is 59 degrees Celsius and the presence of methylation is indicative of Bladder cancer."],"number":48,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, comprising the primers according to SEQ ID NO.: 60 and 61 for the detection of methylation status of PITX2 as defined in SEQ ID NO.: 8, wherein the primer annealing temperature during amplification is 60 degrees Celsius and the presence of methylation is indicative of Breast cancer."],"number":49,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, comprising the primers according to SEQ ID NO.: 68 and 69 for the detection of methylation status of MLH1 as defined in SEQ ID NO.: 12, wherein the primer annealing temperature during amplification is 62 degrees Celsius and the presence of methylation is indicative of Colon cancer."],"number":50,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, comprising the primers according to SEQ ID NO.: 72 and 73 for the detection of methylation status of MSH6 as defined in SEQ ID NO.: 14, wherein the primer annealing temperature during amplification is 59 degrees Celsius and the presence of methylation is indicative of Endometrial cancer."],"number":51,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, further comprising a step of analyzing the amplified CpG-containing nucleic acids of step b)."],"number":52,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 52, wherein said analysis of the amplified CpG-containing nucleic acid is selected from the group consisting of melting curve analysis, high resolution melting analysis, nucleic acid sequencing, primer extension, denaturing gradient gel electrophoresis, southern blotting, restriction enzyme digestion, methylation-sensitive single-strand conformation analysis (MS-SSCA) and denaturing high performance liquid chromatography (DHPLC)."],"number":53,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 53, wherein said analysis of the amplified CpG-containing nucleic acid is melting curve analysis."],"number":54,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 54, wherein said melting curve analysis comprise normalization of melting curves by calculation of the ‘line of best fit’ in between two normalization regions before and after a major fluorescence decrease."],"number":55,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 54, wherein a melting profile displays at least one peak melting temperature."],"number":56,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 54, wherein a melting profile displays at least two peak melting temperatures."],"number":57,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 54, wherein the relative amount of methylated CpG-containing nucleic acid is estimated by comparison with melting curve analysis of at least one standard sample comprising said CpG-containing nucleic acid."],"number":58,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 58, wherein a higher melting temperature of the amplified nucleic acid sample than of the standard sample is indicative of a higher relative amount of methylated nucleic acid of that sample than of the standard sample."],"number":59,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 58, wherein a lower melting temperature of the amplified nucleic acid sample than of the standard sample is indicative of a lower relative amount of methylated nucleic acid of that sample than of the standard sample."],"number":60,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 58, wherein said at least one standard sample comprise any combination of methylated and unmethylated CpG-containing nucleic acid."],"number":61,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 58, wherein said at least one standard sample comprise 100% methylated CpG-containing nucleic acid."],"number":62,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 58, wherein said at least one standard sample comprise 100% unmethylated CpG-containing nucleic acid."],"number":63,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 58, wherein said at least one standard sample comprise 50% methylated nucleic acid and 50% unmethylated CpG-containing nucleic acid."],"number":64,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 54, wherein said melting curve analysis is performed by measurement of fluorescence."],"number":65,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 65, wherein said fluorescence is measured immediately after amplification."],"number":66,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 65, wherein said fluorescence is measured by at least one fluorescent agent selected from the group consisting of ethidium bromide, EvaGreen, LC Green, Syto9, SYBR Green, SensiMix HRM™ kit dye."],"number":67,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 67, wherein said fluorescent agent is SYBR Green I."],"number":68,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 67, wherein aid fluorescent agent is Syto9."],"number":69,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 65, wherein said peak melting temperature corresponds to the highest level of the negative derivative of fluorescence (−dF/dT) over temperature versus temperature (T)."],"number":70,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 54, wherein said melting curve analysis is performed by using a thermal cycler coupled to a fluorometre."],"number":71,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 54, wherein said melting curve analysis is performed by incubating the nucleic acid amplification product at increasing temperatures, from 70 to 95 degrees Celsius, wherein the temperature increases by 0.05 degrees per second."],"number":72,"annotation":false,"title":false,"claim":true},{"lines":["A kit for the detection of methylation status of a CpG-containing nucleic acid in a sample, said kit comprising at least one methylation-independent oligonucleotide primer, which comprises at least one CpG dinucleotide."],"number":73,"annotation":false,"title":false,"claim":true},{"lines":["The kit according to claim 73, further comprising at least one reference sample comprising control CpG-containing nucleic acid."],"number":74,"annotation":false,"title":false,"claim":true},{"lines":["The kit according to claim 73, further comprising an agent that modifies unmethylated cytosine nucleotides."],"number":75,"annotation":false,"title":false,"claim":true},{"lines":["The kit according to claim 75, wherein the reagent that modifies unmethylated cytosine nucleotides is bisulphite."],"number":76,"annotation":false,"title":false,"claim":true},{"lines":["The kit according to claim 73, further comprising instructions for the performance of the detection method of the kit, and for the interpretation of the results."],"number":77,"annotation":false,"title":false,"claim":true},{"lines":["The kit according to claim 73, further comprising software comprising algorithm for calculation of primer annealing temperature and interpretation of results."],"number":78,"annotation":false,"title":false,"claim":true},{"lines":["The kit according to claim 73, further comprising deoxyribonucleoside triphosphates, DNA polymerase enzyme and/or nucleic acid amplification buffer."],"number":79,"annotation":false,"title":false,"claim":true},{"lines":["The kit according to claim 73, wherein the at least one reference sample comprises 100% methylated CpG-containing nucleic acid."],"number":80,"annotation":false,"title":false,"claim":true},{"lines":["The kit according to claim 73, wherein the at least one reference sample comprises 100% unmethylated CpG-containing nucleic acid"],"number":81,"annotation":false,"title":false,"claim":true},{"lines":["The kit according to claim 73, wherein the at least one reference sample comprises 50% methylated and 50% non-methylated nucleic acid."],"number":82,"annotation":false,"title":false,"claim":true},{"lines":["The kit according to claim 73, wherein the CpG-containing nucleic acid has a sequence, which is at least 90% identical to the sequence selected from the group consisting of SEQ ID NO.: 1-45."],"number":83,"annotation":false,"title":false,"claim":true},{"lines":["The kit according to claim 73, wherein the CpG-containing nucleic acid has a sequence, which is at least 90% identical to the sequence selected from the group consisting of SEQ ID NO.: 152-184."],"number":84,"annotation":false,"title":false,"claim":true},{"lines":["The kit according to claim 73, wherein the primers are selected from the group consisting of SEQ ID NO.: 46-151."],"number":85,"annotation":false,"title":false,"claim":true},{"lines":["The kit according to claim 73, wherein the primers are selected from the group consisting of SEQ ID NO.: 185-250."],"number":86,"annotation":false,"title":false,"claim":true},{"lines":["The kit according to claim 73 for diagnosis of a disorder."],"number":87,"annotation":false,"title":false,"claim":true},{"lines":["88-95. (canceled)"],"number":-1,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}